News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
Demand normalisation post the second wave contributed to the steady growth
Income declines marginally
It’s an AB-rated generic therapeutic version of Durezol
A treatment to prevent extreme symptoms and cut hospitalisation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
